Enhance your understanding of the treatment of patients with metastatic colorectal cancer (mCRC) and early CRC via videos from prIME Masterclass in Colorectal Cancer, held in Dubai, United Arab Emirates. The most up-to-date management concepts and emerging treatment strategies for patients with CRC are discussed by the experts and will provide you the tools to apply clinical trial data to real clinical practice.
Apr 5, 2018
Apr 5, 2019
Keynote presentation I—Contemporary personalized management of advanced CRC in 2018
Demetris Papamichael, MBBS, MD, FRCP
Liver-only metastases: Importance of multidisciplinary treatment approach for optimal patient outcomes
Jose Ramos, MBBch, FCS
Selecting front-line therapy for mCRC
Claus-Henning Köhne, MD
Keynote presentation II—Immunotherapy in mCRC: MSI-high and beyond
Ali Shamseddine, MD, FRCP
Continuum of care in mCRC: Second and later treatment lines
Abdullah Al Sharm, MD
What is new in adjuvant therapy for stage II and III colon cancer?
Fathi M. Azribi, MD, FRCP
CRC in the coming years: What can we expect?
Claus-Henning Köhne, MD
Fathi M. Azribi, MD, FRCP
Abdullah Al Sharm, MDKing Fahad Medical City
Riyadh, Saudi Arabia
Fathi M. Azribi, MD, FRCPTawam Hospital
Al Ain, United Arab Emirates
Claus-Henning Köhne, MDKlinikum Oldenburg
Demetris Papamichael, MBBS, MD, FRCPCyprus Oncology Centre
Jose Ramos, MBBch, FCS Wits University Donald Gordon Medical Centre
Johannesburg, South Africa
Ali Shamseddine, MD, FRCPAmerican University of Beirut Medical Center
This educational activity is specifically designed for medical oncologists, gastroenterologists, surgical and radiation oncologists, and other healthcare professionals from Africa, India, the Middle East, and Russia who are involved in the management of CRC.
Upon completion of this educational activity, participants should be able to:
- Explain state-of-the-art management of early and mCRC, and evaluate current and emerging biomarkers to guide personalized therapy
- Identify multidisciplinary treatment approaches that may lead to optimal treatment outcomes for patients with liver-only metastases
- Select optimal front-line treatment for patients with mCRC and assess sequencing strategies beyond disease progression
- Evaluate treatment options for metastatic BRAF-mutant mCRC
- Describe emerging agents in mCRC, including immunotherapy-based combinations
This educational activity is supported by a grant from Merck KGaA, Darmstadt, Germany.
Independent Medical Education (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
This activity is provided by prIME Oncology.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Al Sharm has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Azribi has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Köhne has disclosed that he has received speaking and teaching fees from Amgen, Merck, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Papamichael has disclosed consulting on advisory boards for Merck, Novartis, and Roche. He has also received consulting fees from Cyprus Oncology Centre. Dr Papamichael has received honoraria from Amgen, Merck, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Ramos has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Shamseddine has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Bojana Pajk, MD, MSc (medical director content reviewer/planner) – no relevant financial relationships
- Sanneke Koekkoek, RN (clinical content reviewer/planner) – no relevant financial relationships
- Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.